Sionna Therapeutics to Participate in Upcoming December Investor Conferences

Core Insights - Sionna Therapeutics is focused on developing innovative treatments for cystic fibrosis (CF) by normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein [2][4] - The company is advancing a pipeline of small molecules aimed at correcting defects caused by the F508del genetic mutation, which is significant for improving clinical outcomes for CF patients [2] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing CF treatment through novel medicines that stabilize CFTR's nucleotide binding domain 1 (NBD1) [2] - The company aims to deliver differentiated medicines that restore CFTR function to near-normal levels, potentially enhancing the quality of life for individuals with CF [2] - Sionna is also developing a portfolio of complementary CFTR modulators designed to work synergistically with its NBD1 stabilizers [2] Investor Engagement - Sionna will participate in upcoming investor events, including the Annual Evercore Healthcare Conference on December 3, 2025, and the Citi 2025 Global Healthcare Conference on December 4, 2025 [4] - Live webcasts of these presentations will be available on Sionna's Investor Relations website, with replays accessible after the events [1][3]